Prostanoid Receptors

Dazmegrel is a thromboxane synthetase inhibitor that effectively reduces the synthesis of Thromboxane A2 (TXA2), demonstrating antiplatelet and vasodilator properties. This compound is valuable in research focused on thrombosis and the modulation of platelet aggregation, making it a useful tool for studying cardiovascular diseases and related therapeutic interventions.

ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP receptor). It exhibits significant biological activity in preventing thrombus formation by modulating arachidonic acid metabolism. ICI D1542 is utilized in research applications focused on cardiovascular diseases and thrombotic disorders, providing insights into the role of TXA2 in vascular biology.

Ciproquazone is a prostaglandin receptor inhibitor that effectively reduces prostaglandin biosynthesis. It exhibits a relative inhibitory potency that falls between indomethacin and aspirin, making it a relevant tool for research in inflammatory processes. Its reversible mode of action allows for precise modulation in experimental settings, facilitating studies in pain management and related pharmacological applications.

LG 82-4-01 is a selective thromboxane (TX) synthetase inhibitor, exhibiting an IC50 of 1.3 μM. This compound effectively inhibits the synthesis of thromboxanes, which are implicated in various cardiovascular and inflammatory processes. LG 82-4-01 is useful in studying TX-mediated pathways and assessing potential therapeutic interventions in related diseases.

Camonagrel is a potent inhibitor of Prostaglandin E2, targeting thromboxane synthase to decrease the biosynthesis of thromboxane. This compound exhibits significant anti-inflammatory properties and is useful in research applications focused on cardiovascular disease and inflammation pathways. Its inhibition of Prostaglandin E2 makes it a valuable reagent for studies investigating platelet aggregation and vascular function.

CAY10509 is a potent inhibitor of the FP receptor, characterized by an IC50 value of 30 nM. As a PGF2α analog, it serves as a valuable tool for investigating physiological regulatory mechanisms associated with prostaglandin signaling. This reagent is suitable for applications in pharmacological studies and the exploration of inflammatory processes in various biological systems.

MF-592 is a potent inhibitor of the prostaglandin E2 (PGE2) receptor, demonstrating an IC50 value of 3 nM. This compound exhibits favorable pharmacokinetic properties in both rat and dog models, making it a valuable tool for research in inflammation and pain modulation. Its selective inhibition of PGE2 signaling pathways supports studies aimed at understanding various biological processes and developing therapeutic strategies for related diseases.

12(S)-Hydroxy-16-heptadecynoic acid is a mechanism-based inhibitor of cytochrome P450 ω-hydroxylase, effectively targeting this enzyme to modulate its activity. With a Ki value of 1.8 μM, it demonstrates significant inhibitory potency against prostaglandin ω-hydroxylase. This compound is valuable for research applications involving metabolic studies and the modulation of lipid biosynthesis pathways.

12(S)-HPEPE is a potent inhibitor of prostaglandin endoperoxide synthase-2 (PGHS-2), functioning as a lipoxygenase product. This compound demonstrates significant anti-inflammatory activity by reducing interleukin 1h (IL-1h)-induced PGHS-2 expression in human lung microvascular endothelial cells. Its utility in research includes the investigation of inflammatory processes and the modulation of PGHS-2 activity, providing valuable insights into therapeutic strategies for inflammatory diseases.

(±)12-HEPE is a prostaglandin receptor inhibitor produced through the non-enzymatic oxidation of eicosapentaenoic acid (EPA), comprising equal parts of the 12(S)- and 12(R)- isomers. The 12(S) isomer primarily mediates its biological effects in mammalian systems, demonstrating significant inhibition of platelet aggregation with an IC50 of 24 μM, comparable to that of 12-HETE. Additionally, (±)12-HEPE effectively inhibits U46619-induced contraction in rat aorta, exhibiting IC50 values ranging from 8.6 to 8.8 μM, making it valuable for research in cardiovascular and inflammatory responses.

O-Acetylsalicylhydroxamic acid is an acetylation inhibitor targeting prostaglandin H2 synthase (PGHS). It effectively suppresses prostaglandin E2 (PGE2) synthesis and inhibits the cyclooxygenase activity of PGHS in vitro. The compound specifically requires the active site residue Ser-529 for its action on human PGHS-1, with the S529A mutant displaying resistance to its inactivating effects, making it a valuable tool for research in inflammation and pain pathways.

T26A is a highly selective inhibitor of the prostaglandin transporter (PGT), specifically targeting PGT-mediated influx of prostaglandin E2 (PGE2). By blocking PGT activity, T26A effectively elevates extracellular PGE2 levels while reducing intracellular PGE2 metabolites and slowing the metabolism of injected PGE2 in Rattus norvegicus. This compound is valuable for research focused on understanding PGT function in adult animal models without affecting PGE2 synthesis.

Ro 23-3423 is a selective thromboxane synthase inhibitor with an IC50 of 0.33 μM for human platelet microsomal thromboxane synthase. This compound elevates plasma levels of prostaglandin F (PGF) and prostaglandin E2 (PGE2) in a dose-dependent manner, while reducing mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 serves as a valuable tool in the investigation of cardiovascular dynamics and the mechanisms underlying general anesthesia.

KF 13218 is a potent and selective inhibitor of thromboxane B2 (TXB2) synthase, exhibiting an IC50 value of 5.3 ± 1.3 nM. This compound effectively modulates prostaglandin receptor activity, making it valuable for research focused on inflammatory responses and cardiovascular disease pathways. Its long-lasting inhibition of TXB2 synthesis supports investigations into therapeutic strategies for conditions associated with excessive thromboxane production.